Ping Liu

Dr. Ping Liu


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2023 in Hypertension
Verified
Journal Article
Closed access
JHJunshen He
Junshen He
CCChunlin Chen
Chunlin Chen
LXLiqun Xu
Liqun Xu
BXBenheng Xiao
Benheng Xiao
ZCZhao Chen
Zhao Chen
PLPing Liu
Ping Liu
BACKGROUND: Early preeclampsia is associated with significant placental hypoperfusion. We explore the diagnostic value of placental diffusion-derived vessel density (DDVD), a biomarker derived from diffusion-weighted magnetic resonance imaging, which measures in vivo vessel microperfusion, in the differential diagnosis of normal and early preeclampsia pregnancies. METHODS: This was a prospective study involving 29 controls and 17 singleton pregnancies affected by early preeclampsia. Nineteen pregnancies from 28 to 34 weeks of gestational age were included from the normal group for a comparison with the early preeclampsia group. Using a 3.0 T magnetic resonance imaging scanner, diffusion-weighted images were obtained with the diffusion weighting b values of 0, 20, and 40 s/mm 2 . DDVD mean was the mean of DDVD b0b20 and DDVD b0b40 , while DDVD b0b20 and DDVD b0b40 refer to the diffusion-derived vessel density values computed from b =0 and 20 s/mm 2 images, and from b =0 and 40 s/mm 2 images, respectively. The correlation between DDVD mean and gestational age was examined using a linear regression model. The area under the curve of the DDVD mean for early preeclampsia pregnancies detection was calculated by the receiver operating characteristic analysis. RESULTS: As gestational age increased, DDVD mean linearly decreased. DDVD mean was significantly decreased in the early preeclampsia pregnancies compared with the normal pregnancies (52.72±46.73 versus 213.34±93.50 au/pixel; P <0.001). The area under the curve (DDVD mean ) for discriminating between normal and early preeclampsia pregnancies regardless of fetal growth restriction was 0.954, and the area under the curve was 1.000 when early preeclampsia pregnancies without fetal growth restriction were excluded. CONCLUSIONS: DDVD mean , an in vivo vessel microperfusion measure, allowed total separation of normal and early preeclampsia pregnancies.

6 March 2020 in BMC Cancer
Verified
Journal Article
Open access
PDF file
PLPing Liu
Ping Liu
LLLihong Lin
Lihong Lin
YKYanxiang Kong
Yanxiang Kong
ZHZhifeng Huo
Zhifeng Huo
LZLin Zhu
Lin Zhu
CCChunlin Chen
Chunlin Chen
Background: This study aimed to compare the survival outcomes of radio-chemotherapy (R-CT) and radical hysterectomy with postoperative standard therapy (RH) in stage IB1-IIA2 cervical cancer patients. Methods: Based on the large amount of diagnostic and treatment cervical cancer data in China, a real-world study and 1:1 case-control matching were used to compare overall survival (OS) and disease-free survival (DFS) in cervical cancer patients. Results: In this real-world study, the 5-year OS and DFS in the R-CT group (n = 8949) were lower than those in the RH group (n = 18,152). After applying the inclusion criteria, the OS and DFS in the R-CT group (n = 582) were lower than those in the RH group (n = 4308). After 1:1 case-control matching, the 5-year OS and DFS in the R-CT group (n = 535) were lower than those in the RH group (n = 535) (OS: 76.1% vs. 84.6%, p < 0.001, HR = 1.819; DFS: 75.1% vs. 81.5%, p < 0.001, HR = 1.462, respectively). Further stratification showed that for stage IB1 and IIA1 patients, the 5-year OS and DFS in the R-CT group (n = 300) were lower than those in the RH group (n = 300) (OS: 78.9% vs. 87.0%, p < 0.001, HR = 2.160; DFS: 77.0% vs. 84.9%, p < 0.001, HR = 2.053, respectively). In stage IB2 and IIA2 patients, the 5-year OS in the R-CT group (n = 235) was lower than that in the RH group (n = 235) (72.5% vs. 81.5%, p = 0.039; HR = 1.550), but no difference in the 5-year DFS was found between the two groups (72.6% vs. 76.9%, p = 0.151). Conclusions: Our study found that for stage IB1-IIA2 cervical cancer patients, RH offers better overall survival and disease-free survival outcomes than R-CT, however, due to the inherent biases of retrospective study, it needs to be confirmed by randomized trials. In addition, we need to further understand the quality of life of the two treatments. Trial registration: registration number: CHiCTR1800017778; International Clinical Trials Registry Platform Search Port, http://apps.who.int/trialsearch/. registration date: August 14, 2018.

1 August 2021 in Placenta
Verified
Journal Article
Closed access
JHJunshen He
Junshen He
ZCZhao Chen
Zhao Chen
CCChunlin Chen
Chunlin Chen
PLPing Liu
Ping Liu

20 June 2023 in Acta Obstetricia et Gynecologica Scandinavica
Verified
Journal Article
Open access
HDHui Duan
Hui Duan
HLHuimin Li
Huimin Li
SKShan Kang
Shan Kang
HZHongwei Zhao
Hongwei Zhao
BCBiliang Chen
Biliang Chen
CCChunlin Chen
Chunlin Chen
Introduction: FIGO 2018 IIIC remains controversial for the heterogeneity of its prognoses. To ensure a better management of cervical cancer patients in Stage IIIC, a revision of the FIGO IIIC version classification is required according to local tumor size.Material and methods: We retrospectively enrolled cervical cancer patients of FIGO 2018 Stages I–IIIC who had undergone radical surgery or chemoradiotherapy. Based on the tumor factors from the Tumor Node Metastasis staging system, IIIC cases were divided into IIIC‐T1, IIIC‐T2a, IIIC‐T2b, and IIIC‐(T3a+T3b). Oncologcial outcomes of all stages were compared.Results: A total of 63 926 cervical cancer cases were identified, among which 9452 fulfilled the inclusion criteria and were included in this study. Kaplan–Meier pairwise analysis showed that: the oncology outcomes of I and IIA were significantly better than of IIB, IIIA+IIIB, and IIIC; the oncology outcome of IIIC‐(T1‐T2b) was significantly better than of IIIA+IIIB and IIIC‐(T3a+T3b); no significant difference was noted between IIB and IIIC‐(T1‐T2b), or IIIC‐(T3a+T3b) and IIIA+IIIB. Multivariate analysis indicated that, compared with IIIC‐T1, Stages T2a, T2b, IIIA+IIIB and IIIC‐(T3a+T3b) were associated with a higher risk of death and recurrence/death. There was no significant difference in the risk of death or recurrence/death between patients with IIIC‐(T1‐T2b) and IIB. Also, compared with IIB, IIIC‐(T3a+T3b) was associated with a higher risk of death and recurrence/death. No significant differences in the risk of death and recurrence/death were noted between IIIC‐(T3a+T3b) and IIIA+IIIB.Conclusions: In terms of oncology outcomes of the study, FIGO 2018 Stage IIIC of cervical cancer is unreasonable. Stages IIIC‐T1, T2a, and T2b may be integrated as IIC, and it might be unnecessary for T3a/T3b cases to be subdivided by lymph node status.

1 January 2023 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
CLCong Liang
Cong Liang
PLPing Liu
Ping Liu
SKShan Kang
Shan Kang
WLWeili Li
Weili Li
BCBi-Liang Chen
Bi-Liang Chen
CCChunlin Chen
Chunlin Chen
Liang C, et al. J Gynecol Oncol. 2022 Dec;34:e20. https://doi.org/10.3802/jgo.2023.34.e20